

University of Groningen

Genome-wide association study of kidney function decline in individuals of European descent

Gorski, Mathias; Tin, Adrienne; Garnaas, Maija; McMahon, Gearoid M.; Chu, Audrey Y.; Tayo, Bamidele O.; Pattaro, Cristian; Teumer, Alexander; Chasman, Daniel I.; Chalmers, John

Published in:
Kidney International

DOI:
[10.1038/ki.2014.361](https://doi.org/10.1038/ki.2014.361)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2015

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Gorski, M., Tin, A., Garnaas, M., McMahon, G. M., Chu, A. Y., Tayo, B. O., Pattaro, C., Teumer, A., Chasman, D. I., Chalmers, J., Hamet, P., Tremblay, J., Woodward, M., Aspelund, T., Eiriksdottir, G., Gudnason, V., Harris, T. B., Launer, L. J., Smith, A. V., ... Boeger, C. A. (2015). Genome-wide association study of kidney function decline in individuals of European descent. *Kidney International*, 87(5), 1017-1029. <https://doi.org/10.1038/ki.2014.361>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Genome-wide association study of kidney function decline in individuals of European descent

Mathias Gorski^{1,2,82}, Adrienne Tin^{3,82}, Maija Garnaas^{4,82}, Gearoid M. McMahon^{5,6}, Audrey Y. Chu⁷, Bamidele O. Tayo⁸, Cristian Pattaro⁹, Alexander Teumer¹⁰, Daniel I. Chasman⁷, John Chalmers¹¹, Pavel Hamet¹², Johanne Tremblay¹³, Marc Woodward¹¹, Thor Aspelund^{14,15}, Gudny Eiriksdottir¹⁴, Vilmundur Gudnason^{14,15}, Tamara B. Harris¹⁶, Lenore J. Launer¹⁶, Albert V. Smith^{14,15}, Braxton D. Mitchell^{17,18}, Jeffrey R. O'Connell¹⁷, Alan R. Shuldiner^{17,18}, Josef Coresh^{3,19}, Man Li³, Paul Freudenberger²⁰, Edith Hofer²¹, Helena Schmidt²⁰, Reinhold Schmidt²², Elizabeth G. Holliday²³, Paul Mitchell²⁴, Jie Jin Wang²⁴, Ian H. de Boer²⁵, Guo Li²⁶, David S. Siscovick^{26,27}, Zoltan Kutalik^{28,29}, Tanguy Corre²⁸, Peter Vollenweider³⁰, Gérard Waeber³⁰, Jayanta Gupta³¹, Peter A. Kanetsky³¹, Shih-Jen Hwang⁶, Matthias Olden^{1,6}, Qiong Yang^{6,32}, Mariza de Andrade³³, Elizabeth J. Atkinson³³, Sharon L.R. Kardia³⁴, Stephen T. Turner³³, Jeanette M. Stafford³⁵, Jingzhong Ding³⁶, Yongmei Liu³⁷, Cristina Barlassina³⁸, Daniele Cusi^{38,39}, Erika Salvi³⁸, Jan A. Staessen^{40,41}, Paul M. Ridker⁷, Harald Grallert^{42,43,44}, Christa Meisinger⁴², Martina Müller-Nurasyid^{45,46,47,48}, Bernhard K. Krämer⁴⁹, Holly Kramer⁸, Sylvia E. Rosas⁵⁰, Ilja M. Nolte^{51,52}, Brenda W. Penninx^{53,54}, Harold Snieder^{51,52}, M. Fabiola Del Greco⁵⁵, Andre Franke⁵⁶, Ute Nöthlings^{57,58}, Wolfgang Lieb⁵⁹, Stephan J.L. Bakker⁶⁰, Ron T. Gansevoort⁶⁰, Pim van der Harst⁶¹, Abbas Dehghan⁶², Oscar H. Franco⁶², Albert Hofman⁶², Fernando Rivadeneira⁶², Sanaz Sedaghat⁶², André G. Uitterlinden⁶², Stefan Coassin⁶³, Margot Haun⁶³, Barbara Kollerits⁶³, Florian Kronenberg⁶³, Bernhard Paulweber⁶⁴, Nicole Aumann⁶⁵, Karlhans Endlich⁶⁶, Mike Pietzner⁶⁷, Uwe Völker¹⁰, Rainer Rettig⁶⁸, Vincent Chouraki⁶⁹, Catherine Helmer⁷⁰, Jean-Charles Lambert⁷¹, Marie Metzger⁷², Benedicte Stengel⁷², Terho Lehtimäki⁷³, Leo-Pekka Lyytikäinen⁷³, Olli Raitakari^{74,75}, Andrew Johnson⁷⁶, Afshin Parsa¹⁷, Murielle Bochud⁷⁷, Iris M. Heid^{1,46}, Wolfram Goessling^{78,79}, Anna Köttgen^{3,80}, W.H. Linda Kao^{3,19,83}, Caroline S. Fox^{6,81} and Carsten A. Böger²

¹Department of Genetic Epidemiology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany; ²Department of Nephrology, University Hospital Regensburg, Regensburg, Germany; ³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA; ⁴Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; ⁵Division of Nephrology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA; ⁶NHLBI's Framingham Heart Study, National Heart, Lung and Blood Institute, Framingham, Massachusetts, USA; ⁷Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; ⁸Department of Public Health Services, Loyola Medical Center, Loyola University Chicago, Maywood, Illinois, USA; ⁹Center for Biomedicine, European Academy of Bozen/Bolzano (EURAC), affiliated to the University of Lübeck, Bolzano, Italy; ¹⁰Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany; ¹¹George Institute for Global Health, University of Sydney, Sydney, New South Wales, Australia; ¹²Centre de recherche du Centre hospitalier de l'Université de Montréal, University of Montreal, Montreal, Quebec, Canada; ¹³CHUM Research Center- Technopôle Angus, Montreal, Québec, Canada; ¹⁴Icelandic Heart Association, Research Institute, Kopavogur, Iceland; ¹⁵University of Iceland, Reykjavik, Iceland; ¹⁶Intramural Research Program, Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, Bethesda, Maryland, USA; ¹⁷Department of Medicine and Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA; ¹⁸Geriatric Research and Education Clinical Center, Veterans Administration Medical Center, University of Maryland School of Medicine, Baltimore, Maryland, USA; ¹⁹Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland, USA; ²⁰Institute of Molecular Biology and Biochemistry, Medical University Graz, Graz, Austria; ²¹Department of Neurology, Institute for Medical Informatics, Statistics and Documentation, Medical University Graz, Graz, Austria; ²²Department of Neurology, Medical University Graz, Graz, Austria; ²³Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, CReditSS, HMRI, Callaghan, New South Wales, Australia; ²⁴Centre for Vision Research, Westmead Millennium Institute, University of Sydney, Westmead Hospital, Sydney, New South Wales, Australia; ²⁵University of Washington, Seattle, Washington, USA; ²⁶Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, USA; ²⁷New York Academy of Medicine, New York, New York, USA; ²⁸Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland; ²⁹Department of Medical Genetics, Swiss Institute of Bioinformatics, Lausanne, Switzerland; ³⁰Internal Medicine Department, Lausanne University Hospital,

Lausanne, Switzerland; ³¹Perelman School of Medicine at the University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics; ³²Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA; ³³Mayo Clinic, Rochester, Minnesota, USA; ³⁴University of Michigan, Ann Arbor, Michigan, USA; ³⁵Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; ³⁶Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; ³⁷Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; ³⁸Department of Health Science, University of Milano, Milano, Italy; ³⁹Division of Nephrology, San Paolo Hospital, Milano, Italy; ⁴⁰Department of Epidemiology, Maastricht University, Maastricht, The Netherlands; ⁴¹Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; ⁴²Institute of Epidemiology II, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany; ⁴³Research Unit of Molecular Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany; ⁴⁴German Center for Diabetes Research, Neuherberg, Germany; ⁴⁵DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; ⁴⁶Institute of Genetic Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany; ⁴⁷Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany; ⁴⁸Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-Universität, Munich, Germany; ⁴⁹University Medical Centre Mannheim, 5th Department of Medicine, University of Heidelberg, Mannheim, Germany; ⁵⁰Joslin Diabetes Center and Beth Israel Medical Center, Harvard Medical School, Boston, Massachusetts, USA; ⁵¹Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; ⁵²Unit of Genetic Epidemiology and Bioinformatics, Department of Epidemiology (FA40), University Medical Center Groningen, Groningen, The Netherlands; ⁵³Department of Psychiatry/EMGO Institute/ Neuroscience Campus, VU University Medical Centre, Amsterdam, The Netherlands; ⁵⁴EMGO Institute Vumc, NESDA, Amsterdam, The Netherlands; ⁵⁵Center for Biomedicine, European Academy of Bozen/Bolzano (EURAC), affiliated to the University of Lübeck, Bolzano, Italy; ⁵⁶Institute of Clinical Molecular Biology, Kiel, Germany; ⁵⁷Popgen Biobank, University Hospital Schleswig-Holstein, Kiel, Germany; ⁵⁸Section for Epidemiology, Institute for Experimental Medicine, Christian-Albrechts-University of Kiel, Kiel, Germany; ⁵⁹Institute of Epidemiology and Biobank popgen, Christian-Albrechts University, Kiel, Germany; ⁶⁰University Medical Center Groningen, Department of Nephrology, University of Groningen, Groningen, The Netherlands; ⁶¹University Medical Center Groningen, Department of Cardiology, University of Groningen, Groningen, The Netherlands; ⁶²Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands; ⁶³Division of Genetic Epidemiology, Innsbruck Medical University, Innsbruck, Austria; ⁶⁴First Department of Internal Medicine, Paracelsus Private Medical University Salzburg, Salzburg, Austria; ⁶⁵Department SHIP/KEF, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany; ⁶⁶Institute of Anatomy and Cell Biology, University Medicine Greifswald, Greifswald, Germany; ⁶⁷Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany; ⁶⁸Institute of Physiology, University of Greifswald, Greifswald-Karlsburg, Germany; ⁶⁹Inserm, U744, Institut Pasteur de Lille, Université Lille-Nord de France, CHR&U de Lille, Service d'épidémiologie régionale, CHRU, Lille, France; ⁷⁰Inserm, U897, Université Bordeaux 2, ISPED, ISPED, Université Bordeaux 2, Bordeaux, France; ⁷¹Inserm, U744, Institut Pasteur de Lille, Université Lille-Nord de France, Institut Pasteur, Lille, France; ⁷²Inserm, U1018, University Paris-Sud, CESP Team 10, Villejuif, France; ⁷³Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland; ⁷⁴Department of Clinical Physiology, Turku University Hospital, Turku, Finland; ⁷⁵Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland; ⁷⁶NHLBI Cardiovascular Epidemiology and Human Genomics Branch, Framingham Heart Study, National Heart, Lung and Blood Institute, Framingham, Massachusetts, USA; ⁷⁷Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Epalinges, Switzerland; ⁷⁸Divisions of Genetics and Gastroenterology, Department of Medicine, Brigham and Women's Hospital, and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; ⁷⁹Harvard Stem Cell Institute, Harvard University and Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; ⁸⁰Renal Division, Freiburg University Clinic, Germany, Freiburg, Germany and ⁸¹Department of Endocrinology, Brigham and Women's Hospital, Boston, Massachusetts, USA

Genome-wide association studies (GWASs) have identified multiple loci associated with cross-sectional eGFR, but a systematic genetic analysis of kidney function decline over time is missing. Here we conducted a GWAS meta-analysis among 63,558 participants of European descent, initially from 16 cohorts with serial kidney function measurements within the CKDGen Consortium, followed by independent replication among additional participants from 13 cohorts.

In stage 1 GWAS meta-analysis, single-nucleotide polymorphisms (SNPs) at *MEOX2*, *GALNT11*, *IL1RAP*, *NPPA*, *HPCAL1*, and *CDH23* showed the strongest associations for at least one trait, in addition to the known *UMOD* locus, which showed genome-wide significance with an annual change in eGFR. In stage 2 meta-analysis, the significant association at *UMOD* was replicated. Associations at *GALNT11* with Rapid Decline (annual eGFR decline of 3 ml/min per 1.73 m² or

Correspondence: Carsten A. Böger, Department of Nephrology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, 93042, Germany. E-mail: carsten.boeger@klinik.uni-regensburg.de

⁸²These authors contributed equally to this work.

⁸³Deceased.

Received 31 January 2014; revised 4 September 2014; accepted 11 September 2014; published online 10 December 2014

more), and *CDH23* with eGFR change among those with CKD showed significant suggestive evidence of replication. Combined stage 1 and 2 meta-analyses showed significance for *UMOD*, *GALNT11*, and *CDH23*. Morpholino knockdowns of *galnt11* and *cdh23* in zebrafish embryos each had signs of severe edema 72 h after gentamicin treatment compared with controls, but no gross morphological renal abnormalities before gentamicin administration. Thus, our results suggest a role in the deterioration of kidney function for the loci *GALNT11* and *CDH23*, and show that the *UMOD* locus is significantly associated with kidney function decline.

Kidney International (2015) **87**, 1017–1029; doi:10.1038/ki.2014.361; published online 10 December 2014

KEYWORDS: chronic kidney disease; genome-wide association study; kidney function decline; kidney development; population genetics; single nucleotide polymorphism; zebrafish

Chronic kidney disease (CKD) is an important public health problem affecting up to 10% of adults worldwide.^{1–3} Faster rates of decline in estimated glomerular filtration rate (eGFR), and entry into CKD stages of increasing severity, are associated with an increased risk of cardiovascular and all-cause mortality.^{4–9} Thus, recently issued guidelines on the evaluation and management of patients with CKD have highlighted the importance of evaluating longitudinal measures of renal function in addition to determining eGFR and urinary albumin excretion at discrete time points.³

Traditional risk factors for CKD include diabetes and hypertension, but these do not fully account for CKD risk.¹⁰ There is evidence for considerable clustering of CKD within families¹¹ and the heritability of eGFR has been estimated at up to 36–75% in population-based studies.¹² Using genome-wide association studies (GWASs), multiple loci have been identified in association with eGFR and CKD in both European^{13–16} and non-European populations^{17,18} using data from one time point. However, multiple lines of evidence suggest that there may be unique genetic contributions to renal function decline above and beyond baseline renal function. First, there is substantial variability in the rate of eGFR decline in studies of healthy persons as well as among those with CKD.^{3,4,19,20} Second, we have previously shown that some genetic loci associated with cross-sectional eGFR are also associated with incident CKD (CKDi) even after accounting for baseline eGFR.²¹ Finally, the genetic background has been shown to affect CKD progression in animal models.^{22,23}

Taken together, these data suggest that unique loci may exist for renal function decline in addition to those identified for a one-time measure of eGFR. Thus, we conducted a GWAS meta-analysis among participants from 16 cohorts with serial kidney function measurements within the CKDGen Consortium, followed by independent replication among additional participants from 13 cohorts.

RESULTS

Study participants

Changes in renal function over time were derived from 45,530 individuals who participated in stage 1 meta-analysis of study-specific GWAS, and an additional 18,028 independent individuals who participated in stage 2 meta-analysis (Table 1). Details on study design and genotyping are provided in Supplementary Tables S1 and S2 online, respectively.

At the baseline examination, the prevalence of CKD, defined as eGFR < 60 ml/min per 1.73 m², ranged from 3.2 to 21.4% in stage 1 cohorts and from 0.2 to 23.9% in stage 2 replication cohorts. As expected, cohorts with lower mean age at baseline tended to have a lower baseline prevalence of CKD. Four kidney function decline traits were derived from serial eGFR values in each study participant to model mechanisms underlying different rates of kidney function change over time: (i) annual decline of eGFR (eGFRchange, in ml/min per 1.73 m² decline per year; a positive value represents a decline in eGFR, whereas a negative value

Table 1 | Stage 1 and Stage 2 cohort characteristics

		Age at baseline, years	% Women, n	%HTN at baseline, n	%DM at baseline, n	%CKD at baseline, n	eGFR baseline, ^a ml/min per 1.73 m ²	eGFR follow-up, ^a ml/min per 1.73 m ²	Duration between baseline and follow-up (years) mean, s.d.
Stage 1 discovery cohorts									
AGES	3219	54.2 (8.98)	58.0, 1867	21.6, 694	3.2, 103	3.2, 104	89.6 (19.3)	73.0 (20.0)	22.2 (6.7)
Amish	458	46.9 (14.3)	54.4, 249	8.7, 40	4.2, 19	NA	95.9 (24.3)	89.2 (19.4)	5.2 (2.6)
ARIC	9049	54.5 (5.7)	52.9, 4793	26.9, 2427	8.6, 780	2.9, 260	89.7 (17.0)	83.5 (17.1) ^A 80.6 (17.1) ^B	8.0 (2.2)
ASPS	848	65.8 (8.1)	56.8, 482	72.5, 615	9.8, 83	12.7, 108	80.2 (20.2)	74.6 (15.1)	5.5 (2.0)
CHS	2820	71.9 (5.0)	61.3, 1729	34.5, 966	11.0, 310	7.9, 224	77.3 (20.8)	75.4 (20.2)	5.9 (1.8)
Colaus	1918	53.9 (10.8)	54.9, 1053	35.4, 679	6.31, 121	5.0, 95	91.5 (20.4)	84.9 (18.2)	5.58 (0.29)
FHS (Offspring and Cohort)	2523	58.1 (8.6)	55.6, 1405	36.8, 927	8.1, 206	8.3, 210	88.7 (25.5)	79.5 (19.1)	11.1 (3.6)
GENOA	1041	54.7 (10.3)	55.6, 579	71.7, 746	8.8, 92	4.3, 45	92.1 (20.7)	89.8 (22.8)	4.0 (1.1)
HABC	888	73.4 (2.8)	48.5, 431	33.1, 294	8.5, 75	21.4, 190	71.8 (13.2)	72.9 (21.2)	9.0 (0.3)
JUPITER	8780	66.1 (7.8)	32.2, 2826	63.8, 5602	0.6, 54	11.5, 1008	80.1 (18.1)	78.2 (17.7)	2.6 (1.0)
KORA3	1641	52.5 (10.1)	49.5, 813	38.3, 629	4.3, 71	3.2, 53	91.3 (18.0)	83.9 (21.0)	10 (0)
KORA4	1807	53.8 (8.9)	51.3, 927	33.7, 606	3.7, 66	3.9, 70	89.5 (17.5)	85.1 (20.2)	7.1 (0.4)
MESA	2324	63.2 (10.1)	51.7, 1201	37.3, 866	5.5, 135	13.3, 310	74.2 (13.9)	70.7 (15.1)	4.8 (0.5)
The Rotterdam Study (RS-I)	2422	66.5 (7.0)	60.2, 1459	50.8, 1230	7.5, 182	7.7, 186	79.9 (15.5)	73.7 (15.8)	6.5 (0.4)
SHIP	3203	49.2 (15.3)	51.8, 1659	24.3, 778	7.0, 225	3.7, 119	92.4 (19.8)	90.6 (23.6)	5.3 (0.7)
Three Cities (3C)	2589	73.0 (4.5)	61.9, 1602	76.7, 1986	8.6, 223	18.9, 489	73.1 (16.1)	71.0 (16.8)	3.8 (0.3)
Stage 2 replication cohorts									
ADVANCE	2034	67.0 (6.6)	31.9, 649	55.2, 1123	100, 2034	16.0, 325	84.1 (28.1)	84.8 (34.5)	4.9 (0.9)
BMES	1304	62.9 (7.7)	60.1, 784	67.1, 875	5.4, 71	23.9, 312	82.6 (31.7)	75.5 (34.9)	10.4 (0.6)
COLAUS	2238	53.1 (10.4)	53.9, 1207	24.0, 538	4.1, 91	3.5, 79	90.5 (19.5)	88.7 (18.7)	5.5 (0.3)
HYPERGENES	651	53.4 (7.5)	45.3, 295	13.9, 91	0	0.61, 4	107.4 (23.5)	103.4 (35.1)	5.6 (3.2)
KORA3	1494	51.6 (13.3)	52.5, 785	29.4, 437	5.1, 76	2.6, 39	98.0 (20.1)	92.4 (21.3)	9.6 (0.6)
KORA4	1200	49.2 (15.4)	52.4, 629	13.3, 159	4, 48	5.8, 70	97.4 (21.7)	92.6 (22.4)	7.2 (0.5)
NESDA	1270	43.3 (12.3)	67.2, 854	32.4, 411	5.4, 69	0.9, 11	97.8 (20.4)	95.5 (18.5)	2.0 (0.3)
popgen	577	60.2 (9.4)	42.1, 243	50.4, 288	5.2, 30	6.1, 35	84.5 (17.2)	79.9 (18.4)	4.8 (0.8)
PREVEND (4-year follow-up)	791	53.0 (13.3)	50.8, 402	40.8, 323	4.2, 33	6.0, 47	89.2 (19.5)	106.4 (34.2)	4.3 (0.6)
PREVEND (9-year follow-up)	2169	48.0 (11.1)	48.0, 1040	28.2, 612	3.1, 66	1.7, 37	93.7 (17.7)	86.9 (18.6)	9.4 (0.84)
RS-II	1243	61.8 (5.2)	54.6, 679	21.4, 266	7.8, 97	8.6, 186	81.2 (17.0)	73.7 (15.8)	10.6 (0.4)
SAPHIR	1374	51.6 (6.0)	39.0, 536	54.9, 754	2.6, 36	0.9, 13	91.5 (15.8)	88.0 (16.0)	4.6 (0.7)
YFS	1683	31.9 (4.9)	56.0, 943	8.3, 139	1.1, 18	0.2, 3	105.4 (16.4)	100.4 (16.0)	6.0 (0)

Abbreviations: DM, diabetes; eGFR, estimated glomerular filtration rate; HTN, hypertension; NA, not applicable; s.d., standard deviation. Unless indicated otherwise, values are given as mean (s.d.).
A, eGFR at visit 2; B, eGFR at visit 4; CKD, chronic kidney disease (eGFR < 60 ml/min per 1.73 m²).

represents a rise in eGFR over time); (ii) CKDi to select individuals with a decline in kidney function to the clinical outcome CKD stage 3 or higher (CKDi, cases defined as those free of CKD at baseline but eGFR < 60 ml/min per 1.73 m² during follow-up); (iii) CKDi with additionally at least a 25% eGFR decline from baseline to select individuals reaching CKD stage 3 after a sizeable decline in kidney function (CKDi25);²⁴ and (iv) rapid eGFR decline to select individuals with the highest risk of adverse outcomes (Rapid Decline, cases defined as those with annual eGFR decline ≥ 3 ml/min per 1.73 m²).⁵ Most cohorts showed a decline in kidney function over time (Table 1). The distribution of all four traits in stage 1 and stage 2 cohorts can be found in Supplementary Table S3 online.

Heritability of eGFR change

The heritability of eGFR change in the Framingham Heart Study was estimated as 38%, after adjusting for age, sex, and baseline eGFR.

Stage 1 meta-analysis of GWAS of measures of kidney function change over time

Stage 1 GWAS meta-analysis was performed in all samples for all four traits. Two secondary association analyses were performed to account for potentially different rates of kidney function decline in those with and those without CKD: (i) eGFRchange stratified by baseline CKD status and (ii) Rapid Decline in only those without baseline CKD; too few individuals with CKD fulfilled the Rapid Decline criteria to perform this analysis. Supplementary Figure S1 online shows the Manhattan and QQ-plots of the stage 1 meta-analysis of each trait. The genomic control factor ranged from 1.007 to 1.05, suggesting negligible evidence for population stratification.

In GWAS meta-analysis of stage 1 cohorts, the minor T allele of rs12917707 at the *UMOD* locus, previously identified by GWAS to be associated with higher eGFR in cross-sectional analysis,¹⁴ was associated with an increase in eGFR over time at a genome-wide significance level ($P = 2.6 \times 10^{-14}$, Table 2), and showed at least nominally significant, direction-consistent association with all other analyzed phenotypes (Supplementary Table S4 online). In addition, SNPs at the novel *CDH23*, *GALNTL5/GALNT11*, *MEOX2*, *IL1RAP/OSTN*, *C2orf48/HPCAL1*, and *NPPB/NPPA* loci were associated with at least one of the analyzed traits at a significance level of $P < 10^{-6}$ (Table 2). Thus, a total of seven SNPs were moved forward to stage 2 meta-analysis. These SNPs mostly showed high imputation quality in each cohort or were genotyped *de-novo* (Supplementary Table S5 online), and showed low between-study heterogeneity ($I^2 < 25\%$).

Stage 2 meta-analysis

Of the seven loci moved forward for stage 2 meta-analysis, only rs12917707 at *UMOD* was significantly associated with the stage 1 trait after correcting for multiple testing ($P = 4.7 \times 10^{-5}$). Two further SNPs showed suggestive significance (one-sided $P < 0.05$) with their respective stage

Table 2 | Genetic association results of SNPs identified in stage 1 meta-analysis

SNPID	Trait	Chr	Position (b36)	Locus	Coded allele	Non-coded allele	AF coded allele	Discovery stage 1		Replication stage 2		Stage 1 and stage 2 combined	
								β	PVal2GC	β	pval1GC	β	Total sample size
rs12917707	eGFRchange overall	16	20275191	<i>UMOD</i> , <i>PDILT</i>	t	g	0.18	-0.15	2.6×10^{-14}	-0.12	4.7×10^{-5}	-0.14	59,373
rs11803049	eGFRchange CKD	1	11851482	<i>NPPB</i> , <i>NPPA</i> , <i>KIAA2013</i> , <i>CLCN6</i>	a	g	0.07	-0.57	3.6×10^{-7}	0.02	0.43 ^a	-0.27	4116
rs875860	eGFRchange CKD	10	72979535	<i>CDH23</i>	t	c	0.12	-0.49	6.2×10^{-7}	-0.15	0.047 ^a	-0.31	4116
rs11764932	Rapid decline overall	7	15699643	<i>MEOX2</i>	a	g	0.36	0.12	6.8×10^{-8}	0.04	0.14	0.09	61,078
rs1019173	Rapid decline overall	7	151341480	<i>GALNTL5</i> , <i>GALNT11</i> , <i>MLL3</i> , <i>CTSL1</i>	a	g	0.63	-0.12	3.0×10^{-7}	-0.06	0.04	-0.10	61,077
rs9814367	Rapid Decline noCKD	3	192075180	<i>IL1RAP</i> , <i>OSTN</i>	t	c	0.92	-0.20	4.1×10^{-7}	0.02	0.39	-0.13	56,687
rs759341	CKDi25	2	10297660	<i>C2orf48</i> , <i>HPCAL1</i> , <i>RRM2</i>	a	g	0.31	0.18	1.5×10^{-6}	0.06	0.27 ^b	0.16	41,122

Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; SNP, single-nucleotide polymorphism.

^aLocus is based on build 36, hg18. The gene closest to the SNP is listed first and is in boldface if the SNP is located within the gene.

^aStudies included: ADVANCE, BMES, COLAUS, RS-II.

^bStudies included: ADVANCE, BMES, RS-II.




Figure 1 | Regional association plots of the novel loci identified by genome-wide association study (GWAS) of kidney function decline traits. Negative log₁₀ *P* values are plotted vs. genomic position (build 36, hg18). The lead single-nucleotide polymorphism (SNP) in each region is labeled. Other SNPs in each region are color-coded based on their LD to the lead SNP. Light blue lines indicate recombination rate (cM/Mb). (a) *GALNT5/GALNT11* locus. (b) *CDH23* locus.

1 trait: rs875860 in *CDH23* with eGFRchange in those with CKD at baseline, and rs1019173 at *GALNT5/GALNT11* with Rapid Decline (Table 2). There was no significant heterogeneity between studies for these two SNPs (rs875860: $I^2 = 9.7\%$, $P = 0.34$; rs1019173: $I^2 = 32.4\%$, $P = 0.12$) or for the other SNPs analyzed in the stage 2 meta-analysis ($I^2 < 30.0\%$).

The SNP rs1019173 is located in an intron in the *GALNT5* gene, and lies in a linkage disequilibrium block spanning the genes *GALNT11*, *MLL3*, *CCT8L*, and part of the *GALNT5* gene (Figure 1a). The SNP in *CDH23*, rs875860, is an intronic SNP in a linkage disequilibrium block whose boundaries lie within the coding region of the *CDH23* gene (Figure 1b).

In the combined meta-analysis of these three SNPs from both stage 1 and stage 2 cohorts, there was no evidence of between-study heterogeneity in the combined meta-analysis ($I^2 < 25\%$). Only the SNP at *UMOD* showed genome-wide significant association (rs12917707, $P = 1.2 \times 10^{-16}$) in the combined stage 1 and stage 2 analysis, whereas there was suggestive evidence of significance for the two novel loci identified in stage 1 (rs875860 in *CDH23*: $P = 1.5 \times 10^{-6}$ for the association with eGFRchange in those with CKD; rs1019173 at *GALNT5/GALNT11*: odds ratio = 0.91 for the A allele, $P = 2.2 \times 10^{-7}$ for the association with Rapid Decline).

Functional validation of novel loci in zebrafish

To investigate the role of the two suggestive novel loci in vertebrate kidney development and function and to bolster confidence in the nominally significant statistical associations in the replication studies, we knocked down the corresponding genes in the zebrafish using antisense morpholino (MO) technology. We focused on the *CDH23* region and the block containing *GALNT5*, *GALNT11*, *MLL3*, and *CCT8L1*. For the latter region, we focused on *GALNT11* and *MLL3*, because there are no zebrafish *GALNT5* and *CCT8L1* orthologs. Further, we investigated the effect of MO knockdown of *umod*. Following MO injection at the 1-cell stage, we performed *in situ* hybridization for the established renal markers *pax2a* (global kidney) and *nephrin* (podocytes) at 48 h post fertilization (h.p.f.). Compared with control embryos, *cdh23*, *galnt11*, *mlt3a*, *mlt3b*, and *umod* morphants did not display significant defects in glomerular or tubule gene expression (Figure 2a, $n > 25$ embryos per MO injection).

It is possible that morphant embryos develop a kidney function decline phenotype only after exposure to a nephrotoxin, despite observing no differences in renal marker expression at 48 h.p.f. Accordingly, after MO injection, we injected embryos with gentamicin at 48 h.p.f. and observed edema prevalence and severity over the next 3 days. In control embryos,




Figure 2 | *Cdh23* and *galnt11* knockdowns exacerbate nephrotoxic injury in zebrafish embryos. (a) Whole-mount *in situ* hybridization for the global kidney marker *pax2a* (arrowhead denotes the glomerulus; bracket denotes the tubule) and the podocyte marker *nephrlin* demonstrates that morpholino (MO) knockdowns of *cdh23*, *galnt11*, *mll3a*, and *mll3b* do not result in changes in kidney gene expression compared with control embryos at 48 h post fertilization. Similar results were obtained for MO knockdowns of *umod* (images not shown). (b) MO knockdown of *cdh23* and *galnt11* causes embryos to develop edema at a higher frequency than control embryos following gentamicin challenge. Data are presented as number of observed abnormalities per total number of embryos scored at 5, 24, 48, and 72 h post gentamicin injection (h.p.i.), normalized to control experiments. * $P < 0.05$, ** $P < 0.005$ by Fisher's exact test. (c) Graphical representation of edema prevalence in embryos injected with gentamicin in b. (d) Control embryos develop minor (cardiac) edema, whereas *cdh23* and *galnt11* MO-injected embryos develop severe (cardiac, intestinal, ocular) edema 72 h after gentamicin injection.

gentamicin injection predictably resulted in a majority of embryos developing minor (cardiac) edema by 24 h post injection (h.p.i.) (Figure 2b–d). In comparison, *cdh23* and *galnt11* morphants developed significantly more severe (cardiac, intestinal, and ocular) and more frequent edema (Figure 2b–d). Specifically, whereas 10% of control embryos developed severe edema by 72 h.p.i., 43% of *cdh23* morphants ($P = 0.009$) and 55% of *galnt11* morphants ($P = 0.001$) developed severe edema at this time point. Additionally, a significant proportion of *cdh23* (33%, $P = 0.035$) and *galnt11* morphant embryos (46%, $P = 0.005$) injected with gentamicin developed edema earlier compared with controls at 5 h.p.i. In contrast, knockdown of *mll3* or *umod* affected neither kidney development nor susceptibility to gentamicin (Figure 2b and c). Taken together, these data demonstrate that knockdown of *cdh23* and *galnt11* results in altered renal function after a nephrotoxic insult.

Interrogation of novel loci in eSNP databases and the Chronic Renal Insufficiency Cohort (CRIC) study

We interrogated eSNP databases for evidence of SNPs at the *CDH23* and *GALNTL5/GALNT11* loci to evaluate an effect on gene expression²⁵ but found no relevant associations. Similarly, annotation information provided by functional annotation of genetic variants from high-throughput sequencing data (ANNOVAR)²⁶ did not yield genetic variants of potential functional interest within 500 kb of and in linkage disequilibrium ($r^2 > 0.8$ based on HapMap release 22) with the index SNPs.

In Caucasian participants of the CRIC study, a prospective study of patients with CKD at baseline,²⁷ neither SNPs in *GALNTL5/GALNT11* nor SNPs in *CDH23* were associated with eGFRchange ($n = 1476$) or time to a composite renal event that consisted of incident end-stage renal disease or

halving of eGFR ($n = 1585$, with a total of $n = 178$ events; results not shown).

DISCUSSION

Key findings

Our key findings are fourfold. First, we estimate the heritability of eGFR decline as being 38% in the general population of European descent, providing a rationale to search for genetic variants associated with kidney function decline. Second, we extend evidence of a known locus (*UMOD*) previously associated with CKDi and end-stage renal disease^{21,28} by showing genome-wide significant association with kidney function change. Third, we have identified two novel genetic loci (*CDH23* and *GALNTL5/GALNT11*) with suggestive association with kidney function decline phenotypes. Finally, we show that knockdown of the two novel loci in zebrafish renders the nephron susceptible to a nephrotoxic insult.

Our findings in the context of the literature

We extend the current literature by performing the first large-scale GWAS of renal function decline traits in the general population. Previous studies analyzing progression of renal disease in African Americans,^{29–32} individuals of European descent,²¹ healthy nurses,³³ and patients with diabetes,^{34,35} hypertension,³¹ IgA nephropathy,^{36,37} and end-stage renal disease²¹ focused only on candidate genes.

The SNP in *UMOD* has previously been identified in a GWAS of eGFR measured at one time point,¹⁴ and was significantly associated with CKDi and end-stage renal disease in a candidate gene study²¹ and with salt-sensitive hypertension and kidney damage in rodents and humans.³⁸ Our data extend this knowledge base by providing strong evidence that genetic variation at the *UMOD* locus affects different definitions of kidney function decline.

For Rapid Decline, the associated region on chromosome 7 contains the genes *GALNTL5*, *GALNT11*, *MLL3*, and *CCT8L1*, with our zebrafish data suggesting *GALNTL5* and *GALNT11* as the genes of interest. *GALNTL5* encodes the putative polypeptide *N*-acetylgalactosaminyltransferase-like protein 5, which by similarity has a presumed role in O-linked oligosaccharide biosynthesis. Polypeptide *N*-acetylgalactosaminyltransferase 11, encoded by *GALNT11*, is a glycosyl transferase that catalyzes the initial reaction in O-linked oligosaccharide biosynthesis. Studies in *Xenopus* support a role of the gene product in left–right patterning by modulating Notch1 signaling, thus establishing the crucial balance between motile and immotile cilia, and it is also expressed in the developing kidney of zebrafish.^{39,40} Our data suggest that *galnt11* is not essential for kidney development but protects against susceptibility from nephrotoxins.

The region of chromosome 7 also contains a locus (rs7805747 in *PRKAG2*) that was previously identified in a GWAS meta-analysis of cross-sectional eGFR.¹⁵ However, this SNP is independent of rs1019173 ($r^2 = 0.002$, $D' = 0.061$ in the 1000 Genomes Pilot Version 1, hg18); therefore, the novel locus identified in the present study is unlikely tagging the

PRKAG2 locus. Moreover, conditional analysis using genotypes from both SNPs from individual level data from the ARIC study showed that the association between rs1019173 and Rapid Decline is unchanged when controlling for rs7805747 (data not shown).

The other locus identified from this study is an intronic SNP in *CDH23* that is nominally associated with eGFR change in those with CKD at baseline. *CDH23* encodes cadherin 23, a glycoprotein of the cadherin family. Cadherin 23 and protocadherin 15, encoded by *PCDH15*, form the tip-links spanning the stereocilia of the inner ear's hair cells. These tip-links are key contributors to the mechanosensory transduction in hair cells required for hearing.⁴¹ Rare mutations of *CDH23* cause progressive, nonsyndromic deafness (DFNB12, MIM # 601386)^{42–44} or Usher Syndrome 1D, characterized by profound deafness, vestibular dysfunction, and retinitis pigmentosa (MIM # 601067). The transmembrane protein cadherin 23 is expressed in many tissues, including the kidney,^{44,45} where it is found predominantly in the tubulointerstitium.⁴⁶ Although a kidney phenotype has not been reported for patients with DFNB12 or Usher syndrome, our zebrafish data provide evidence that cadherin 23 has a role in protecting from susceptibility to nephrotoxins, while not being essential for nephrogenesis.

Implications

Our GWAS findings point toward two novel gene loci, *CDH23* and *GALNTL5/GALNT11*, and one previously identified locus (*UMOD*) as being associated with kidney function decline. The zebrafish experiments support a role of the two newly identified loci in increasing renal susceptibility to nephrotoxic insults and may indicate that a perturbation model could serve as a model of longitudinal kidney function decline. In a previous work, we have shown that knockdown of two genes identified by GWAS of cross-sectional eGFR, *mpped2* and *casp9*, resulted in abnormal kidney development, with susceptibility to gentamicin only in *casp9* knockdown.¹⁶ Taken together, our current and previous data highlight the differential role of genes in affecting kidney development, function, and susceptibility to damage.

Strengths and limitations

The strengths of this study include the large sample size of renal function decline traits, follow-up in independent samples, analysis of several definitions of kidney function decline, and validation in zebrafish. Some limitations warrant mention. Even though we addressed interassay differences of serum creatinine measurement by calibrating creatinine to representative National Health and Nutrition Examination Study (NHANES) standards, several other factors causing imprecision in defining kidney function decline phenotypes may have reduced our statistical power to identify genome-wide significant associations: (i) despite our use of different renal function decline definitions, all featured in current guideline statements,³ there is no standard definition of renal function decline; (ii) kidney function trajectories are less well defined with two vs. several

serum creatinine measurements given that renal function change may not be linear over time³ and there may be day-to-day alterations in glomerular filtration rate (GFR); (iii) GFR estimation equations are known to be imprecise, especially at $\text{GFR} > 60 \text{ ml/min per } 1.73 \text{ m}^2$; (iv) we observed heterogeneity in design between studies, including a wide range of length of follow-up. We cannot rule out that low statistical power also accounts for the negative finding in the CRIC study. Further, our findings, obtained mainly in general population cohorts, provide novel insights into mechanisms of kidney function decline, but may not be generalizable to cohorts enriched for CKD. This limitation deserves particular attention because of the unexpected observation that, in most cohorts, the subgroup with baseline CKD (defined as $\text{eGFR} < 60 \text{ ml/min per } 1.73 \text{ m}^2$) showed a mean increase in eGFR over time irrespective of length of follow-up interval. This may indicate that, in the CKD subgroup of these cohorts, a baseline $\text{eGFR} < 60 \text{ ml/min per } 1.73 \text{ m}^2$ may not represent progressive CKD with active disease but rather stable disease or imprecise GFR estimation. This highlights that more work with expanded data sets and functional models are necessary to further elucidate the genetics of CKD initiation and progression in population-based studies. Finally, the role of genes contributing to aging and chronic disease in humans may not be entirely modeled by transient MO knockdown and observation of a developmental phenotype: whereas zebrafish allows high throughput modeling of the effects of gene knockdown in a vertebrate organism, the developmental role of specific genes may well be different from homeostatic organ maintenance in the adult. Specifically, *umod* may not have a relevant role in zebrafish renal development or toxin susceptibility.

CONCLUSION

In a large GWAS of kidney function decline phenotypes in individuals of European descent, we showed that a SNP in *UMOD* is associated with kidney function decline phenotypes, and that there is suggestive statistical evidence for two novel loci (*GALNTL5/GALNT11* and *CDH23*). Zebrafish experiments at the two novel loci suggest roles in the deterioration of kidney function after acute injury. Given the complexity of the kidney function decline phenotype, further interrogation of these regions is warranted.

MATERIALS AND METHODS

Ethics statement

In all studies, all participants gave informed consent. All studies were approved by their responsible Research Ethics Committees.

Phenotype definition

Serum creatinine was measured at a minimum of two time points spaced several years apart (2.0–22.2 years, median 5.6 years). In almost all studies, there were only two serum creatinine measurements in total. To be consistent across studies, we used each individual's two creatinine measurements with the longest follow-up in between for phenotype creation in all cohorts (see below). Baseline and follow-up serum creatinine were calibrated to the US nationally representative NHANES data in all discovery and replication studies

to account for between-laboratory variation.⁴⁷ In order to be consistent with our prior work, GFR based on serum creatinine (eGFR_{crea}) was estimated using the four-variable MDRD Study Equation. eGFR_{crea} values $< 15 \text{ ml/min per } 1.73 \text{ m}^2$ were set to 15, and those > 200 were set to $200 \text{ ml/min per } 1.73 \text{ m}^2$.

Several phenotypes were used to model different mechanisms involved in the change in renal function over time, using each individual's two serum creatinine measurements with the longest follow-up. The continuous phenotype eGFRchange, modeling annual change in kidney function, was calculated by subtracting the eGFR at follow-up from the eGFR at baseline and then dividing by the number of years of follow-up for each participant. Thus, a positive value of eGFRchange corresponds to a decline in kidney function over time, whereas a negative value of eGFRchange corresponds to an increase in kidney function over time. Three dichotomous phenotypes were calculated to model kidney function decline phenotypes with different clinical implications:^{5,24} for Rapid Decline, cases were defined as individuals with a rapid decline in kidney function $\geq 3 \text{ ml/min per } 1.73 \text{ m}^2$ per year, and controls as those with a kidney function decline $< 3 \text{ ml/min per } 1.73 \text{ m}^2$ per year.⁶ For CKDi, cases were defined as participants with eGFR at baseline $\geq 60 \text{ ml/min per } 1.73 \text{ m}^2$ declining to an eGFR at follow-up $< 60 \text{ ml/min per } 1.73 \text{ m}^2$; a more stringent definition of CKDi (CKDi25) is restricted to CKDi cases with a decline in eGFR $\geq 25\%$ at follow-up. For both CKDi and CKDi25, controls were defined as those with an eGFR $\geq 60 \text{ ml/min per } 1.73 \text{ m}^2$ at baseline and follow-up.

Heritability of eGFR in the Framingham Heart Study

Heritability of eGFRchange was calculated with the family data of the Framingham Heart Study using the variance components analysis implemented in SOLAR.⁴⁸ eGFRchange was calculated by taking follow-up eGFR (obtained between 2005 and 2008) and subtracting baseline eGFR (obtained in 1995–1998), divided by the number of years of follow-up. Residuals were created after adjusting for age, sex, baseline eGFR, and principal components as necessary. With residuals as response variable, a variance components model with an additive genetic and a random environmental variance component was fitted, where the correlation among relatives attributable to the genetic component is assumed proportional to the kinship coefficient matrix. Heritability is calculated as the ratio of the estimated genetic variance to the total phenotypic variance.

Definition of strata

Kidney function decline is known to differ depending on the level of baseline eGFR. Thus, eGFRchange was analyzed (i) in the overall sample (eGFRchange overall), (ii) in those with $\text{eGFR} \geq 60 \text{ ml/min per } 1.73 \text{ m}^2$ at baseline (eGFRchange noCKD), and (iii) in those with $\text{eGFR} < 60 \text{ ml/min per } 1.73 \text{ m}^2$ at baseline (eGFRchange withCKD). Rapid Decline was analyzed in the overall sample (Rapid Decline overall) and in those with $\text{eGFR} \geq 60 \text{ ml/min per } 1.73 \text{ m}^2$ at baseline (Rapid Decline noCKD). CKDi and CKDi25 were analyzed in the overall sample only.

Stage 1 genome-wide association analyses

All participating studies used a uniform analysis plan and each trait was created using standard programming commands that were provided to collaborating studies. The continuous trait (eGFRchange) was analyzed by linear regression and the dichotomous traits by logistic regression (Rapid Decline, CKDi, CKDi25). Models included the allelic dosage at each marker from imputed study data consisting

of 2.5 million HapMap-II SNPs⁴⁹ on average, based on imputations with different programs and reference panels. Details of genotyping and imputation in each study are shown in Supplementary Table S2 online. We used the additive genetic model, adjusted for age and sex, baseline eGFR, and, where applicable, for study site and principal components.

Stage 1 meta-analysis

For our stage 1 analysis, we used aggregated statistics of 16 population-based GWASs of individuals of European ancestry for each of the longitudinal traits: eGFRchange overall, eGFRchange noCKD, eGFRchange with CKD, Rapid Decline overall, Rapid Decline noCKD, CKDi, and CKDi25. All 16 stage 1 studies contributed data to every trait, except for the AMISH study, which provided data to eGFRchange overall and eGFRchange no CKD only because of low number of CKD cases at baseline and follow-up.

All input files underwent quality control using the GWAtoolbox package in R (<http://www.eurac.edu/GWAtoolbox.html>)⁵⁰ before including them into the meta-analysis. Study data were meta-analyzed assuming fixed effects and using inverse-variance weighting. Thus, the pooled effect β_{pooled} is estimated as $\sum \frac{\beta_i / \text{s.e.}_i}{1 / \text{s.e.}_i^2}$, where β and s.e. are the effect and standard error of the SNPⁱ on the outcome in the i_{th} study. The meta-analyses were performed by METAL. We performed genomic control correction if the inflation factor λ in the study files was greater than 1 (first genomic control correction) or if it was greater than 1 in the meta-analysis result (second genomic control correction).⁵¹

Next, we created a list of independent SNPs (pairwise $r^2 < 0.2$, HAPMAP II release 22) that had a genomic control-corrected P -value $< 10^{-6}$ and minor allele frequency $> 5\%$ in stage 1 meta-analysis and were present in at least 85% of the contributing studies.

Stage 2 meta-analysis

The stage 2 meta-analysis of SNPs identified in stage 1 was performed on the same phenotypes and using the same analysis plan as the stage 1 analysis, and was based on *in silico* genetic data or on *de novo* genotyped variants. Details on each stage 2 study's genotyping and imputation platforms are shown in Supplementary Table S2 online. In addition, we also performed a combined inverse-variance weighted fixed-effects stage 1 and stage 2 meta-analysis using individual study files as input. Studies with less than 50 cases for a dichotomous trait or with an overall sample size of less than 50 for a continuous trait were excluded from the meta-analyses of the corresponding trait. SNPs with a stage 2 meta-analysis one-sided P -value < 0.05 and effect direction consistency with the stage 1 meta-analysis effect direction were defined as showing nominally significant evidence of replication. The I^2 statistic was computed to assess heterogeneity between studies.

Zebrafish functional experiments

Zebrafish were maintained according to established Institutional Animal Care and Use Committees protocols. Zebrafish were injected at the 1-cell stage with 2 nl of 400 μM MO (GeneTools, Philomath, OR) designed to block the ATG start site or an exon-intron splice site of the target gene (Supplementary Table S6 online). Embryos were fixed in 4% paraformaldehyde at the appropriate stages for *in situ* hybridization using well-established protocols (<http://zfin.org/ZFIN/Methods/ThisseProtocol.html>). Renal gene expression was visualized using established markers for *pax2a* (global kidney) and *nephrin* (podocytes).^{52,53} The number of embryos displaying abnormal renal gene expression was compared with uninjected control embryos,

and statistical significance was determined by Fisher's exact test. For the gentamicin nephrotoxin experiment, embryos were injected with MO at the 1-cell stage and then injected with 5 nl of 10 mg/ml gentamicin prepared from one stock solution in the cardiac sinus venosus at 48 h.p.f. after being anesthetized in a 1:20 dilution of 4 mg/ml Tricaine in embryo water. Live embryo development and edema prevalence were documented over the next 3 days.

ACKNOWLEDGMENTS

Stage 1 cohorts:

AGES: This study has been funded by NIH contract N01-AG-1-2100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics Committee, VSN: 00-063. We are indebted to the participants for their willingness to participate in the study.

AMISH: The Amish studies are supported by grants and contracts from the NIH including R01 AG18728 (Amish Longevity Study), R01 HL088119 (Amish Calcification Study), U01 GM074518-04 (PAPI Study), U01 HL072515-06 (HAPI Study), U01 HL084756 and NIH K12RR023250 (University of Maryland MCRDP), NIH P30 DK072488 (Clinical Nutrition Research Unit), the University of Maryland General Clinical Research Center, grant M01 RR 16500, and the Baltimore Veterans Administration Medical Center Geriatrics Research and Education Clinical Center. We thank our Amish research volunteers for their long-standing partnership in research, and the research staff at the Amish Research Clinic for their hard work and dedication.

The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. We thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. AK was supported by the grant KO3598/2-1 (Emmy Noether Programme) of the German Research Foundation.

ASPS: The research reported in this article was funded by the Austrian Science Fond (FWF) grant number P20545-P05 and P13180. The Medical University of Graz supports the databank of the ASPS. The authors thank the staff and the participants of the ASPS for their valuable contributions. We thank Birgit Reinhart for her long-term administrative commitment and Ing Johann Semmler for the technical assistance at creating the DNA bank.

The CHS research reported in this article was supported by contract numbers N01-HC-85079-01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, grant numbers U01 HL080295 and R01 HL087652 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at <http://www.chs-nhlbi.org/pi.htm>. DNA handling and genotyping were supported in part by National Center for Research Resources grant M01RR00425 to the Cedars-Sinai General Clinical Research Center Genotyping core and National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

The CoLaus study received financial contributions from GlaxoSmithKline; the Faculty of Biology and Medicine of Lausanne; and the Swiss National Science Foundation (33CSO-122661; 3200BO-111361/2; 3100AO-116323/1; 310000-112552). MB is supported by the Swiss School of Public Health Plus.

FHS: This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine. The analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. This work was partially supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center.

GENOA: This research was partially supported by the National Heart Lung and Blood Institute of the National Institutes of Health (R01 HL-87660).

The Health Aging and Body Composition Study (Health ABC) was funded by the National Institutes of Aging. This research was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to the Johns Hopkins University, contract number HHSN268200782096C. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging.

The JUPITER trial and the genotyping were supported by AstraZeneca.

KORA studies: The genetic epidemiological work was funded by the NIH subcontract from the Children's Hospital, Boston, USA (HEW, IMH, prime grant 1 R01 DK075787-01A1), the German National Genome Research Net NGFN2 and NGFNplus (HEW, 01GS0823; WK project A3, number 01GS0834), the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ, and by the Else Kröner-Fresenius-Stiftung (P48/08//A11/08 to CAB and BKK; 2012_A147 to CAB and IMH). The kidney parameter measurements in F3 were funded by the Else Kröner-Fresenius-Stiftung (CAB, BKK) and the Regensburg University Medical Center, Germany, and those in F4 by the University of Ulm, Germany (WK). Genome-wide genotyping costs in F3 and F4 were in part funded by the Else Kröner-Fresenius-Stiftung (CAB, BKK). *De novo* genotyping in F3 and F4 were funded by the Else Kröner-Fresenius-Stiftung (CAB, IMH). The KORA research platform and the MONICA Augsburg studies were initiated and financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, by the German Federal Ministry of Education and Research, and by the State of Bavaria. Genotyping was performed in the Genome Analysis Center (GAC) of the Helmholtz Zentrum München. The LINUX platform for computation was funded by the University of Regensburg for the Department of Epidemiology and Preventive Medicine at the Regensburg University Medical Center.

MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA Investigators. Support for MESA is provided by contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, and CTSA UL1-RR-024156.

Rotterdam Study 1: The GWA study was funded by the Netherlands Organisation of Scientific Research NWO Investments (no. 175.010.2005.011, 911-03-012), the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Consortium for Healthy Aging (NCHA) project no. 050-060-810. We thank Pascal Arp, Mila Jhamai, Dr Michael Moorhouse, Marijn Verkerk, and Sander Bervoets for their help in

creating the GWAS database. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, the Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture, and Science, the Ministry for Health, Welfare, and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. We are very grateful to the participants and staff from the Rotterdam Study, the participating general practitioners, and the pharmacists. We thank Dr Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and especially the national German MediGRID and Services@MediGRID part of the German D-Grid, both funded by the German Bundesministerium für Forschung und Technologie under grants #01 AK 803 A-H and #01 IG 07015 G, for access to their grid resources. AD is supported by an NWO grant (vici, 918-76-619).

SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs, as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthcare, Erlangen, Germany, and the Federal State of Mecklenburg, West Pomerania. The University of Greifswald is a member of the 'Center of Knowledge Interchange' program of the Siemens AG.

Three Cities: The work was made possible by the generous participation of the control subjects, the patients, and their families. We thank Dr Anne Boland (CNG) for her technical help in preparing the DNA samples for analyses. This work was supported by the National Foundation for Alzheimer's disease and related disorders, the Institut Pasteur de Lille, and the Centre National de Génotypage. The Three-City Study was performed as part of a collaboration between the Institut National de la Santé et de la Recherche Médicale (INSERM), the Victor Segalen Bordeaux II University, and Sanofi-Synthelabo. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, MGEN, Institut de la Longévité, Agence Française de Sécurité Sanitaire des Produits de Santé, the Aquitaine and Bourgogne Regional Councils, Fondation de France, and the joint French Ministry of Research/INSERM 'Cohortes et collections de données biologiques' program. Lille Génomipole received an unconditional grant from Eisai.

Stage 2 cohorts:

ADVANCE: The genetic epidemiological work was funded by Progenix Inc. and by grants from Genome Quebec and Canadian Institutes for Health Research. The clinical study was managed by the George Institute for International Health (Sydney, Australia) with grants received from Les Laboratoires Servier, France, and from Medical Research Council of Australia. The genotyping was performed at the genomic platform of CRCHUM. We acknowledge the technical help of Carole Long and Mounif Haloui and the bioinformatic analyses performed by Gilles Godefroid, François-Christophe Blanchet-Marais, and François Harvey. The members of the genetic substudy of ADVANCE, Stephen Harrap, and Michel Marre are also acknowledged.

The Blue Mountains Eye Study (BMES) was supported by the Australian National Health and Medical Research Council (NHMRC), Canberra Australia (NHMRC project grant IDs 974159, 211069, and 302068, and Centre for Clinical Research Excellence in Translational Clinical Research in Eye Diseases, CCRE in TCR-Eye, grant ID 529923). The BMES GWAS and genotyping costs were supported by Australian NHMRC, Canberra Australia (NHMRC project grant IDs 512423, 475604, and 529912), and the Wellcome Trust, UK, as part of Wellcome Trust Case Control Consortium 2 (A Viswanathan, P McGuffin,

P Mitchell, F Topouzis, P Foster, grant IDs 085475/B/08/Z and 085475/08/Z). EGH is supported by the NHMRC Fellowship scheme.

HYPERGENES (FP7—HEALTH-F4-2007-201550); INTEROMICS (MIUR—CNR Italian Flagship Project); IC15-CT98-0329-EPOGH; LSHM-CT-2006-037093; HEALTH-2011-278249-EU-MASCARA; and ERC Advanced Grant-2011-294713-EPLORE and the Fonds voor Wetenschappelijk Onderzoek Vlaanderen; Ministry of the Flemish Community; Brussels; Belgium (grants G.0575.06 and G.0734.09)

KORA studies: The genetic epidemiological work was funded by the NIH subcontract from the Children's Hospital, Boston, USA (HEW, IMH, prime grant 1 R01 DK075787-01A1), the German National Genome Research Net NGFN2 and NGFNplus (HEW 01GS0823; WK project A3, number 01GS0834), the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ, and by the Else Kröner-Fresenius-Stiftung (P48/08//A11/08 to CAB and BKK; 2012_A147 to CAB and IMH). The kidney parameter measurements in F3 were funded by the Else Kröner-Fresenius-Stiftung (CAB, BKK) and the Regensburg University Medical Center, Germany, and in F4 by the University of Ulm, Germany (WK). Genome-wide genotyping costs in F3 and F4 were in part funded by the Else Kröner-Fresenius-Stiftung (CAB, BKK). *De novo* genotyping in F3 and F4 were funded by the Else Kröner-Fresenius-Stiftung (CAB, IMH). The KORA research platform and the MONICA Augsburg studies were initiated and financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, by the German Federal Ministry of Education and Research, and by the State of Bavaria. Genotyping was performed in the Genome Analysis Center (GAC) of the Helmholtz Zentrum München. The LINUX platform for computation was funded by the University of Regensburg for the Department of Epidemiology and Preventive Medicine at the Regensburg University Medical Center.

NESDA was supported by the Geestkracht program of ZonMW (grant 10-000-1002), matching funds from universities and mental health-care institutes involved in NESDA. Funding support was also provided by the Netherlands Scientific Organization (904-61-090, 904-61-193, 480-04-004, 400-05-717), Centre for Medical Systems Biology (NWO Genomics), the Neuroscience Campus Amsterdam, the EMGO institute, the European Union (EU/WLRT-2001-01254), and by NIMH (R01 MH059160). Genotyping was funded by the Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health, and analysis was supported by grants from GAIN and the NIMH (MH081802) and the Center for Molecular and Systems Biology. Genotype data were obtained from dbGaP (<http://www.ncbi.nlm.nih.gov/dbgap>), accession number phs000020.v1.p1. Statistical analyses were partly conducted at the Genetic Cluster Computer (<http://www.geneticcluster.org>), which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the Dutch Brain Foundation.

POPGEN: This study was funded by the German National Genome Research Network (NGFN; Federal Ministry of Education and Research, grant numbers 1GS0121, 01GS0171, and 01GR0468) and by the DFG Excellence Cluster 'Inflammation at Interfaces' (EXC 306).

The PREVENT Study was financially supported by several grants from the Dutch Kidney Foundation.

Rotterdam Study II: The GWA study was funded by the Netherlands Organisation of Scientific Research NWO Investments (no. 175.010.2005.011, 911-03-012), the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), and by the Netherlands Genomics Initiative (NGI)/Netherlands Consortium for Healthy Aging (NCHA) project no. 050-060-810. We thank Pascal Arp, Mila Jhamai, Dr Michael Moorhouse, Marijn Verkerk, and Sander Bervoets for their help in creating the GWAS database. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, the Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture, and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. We are very grateful to the participants

and staff from the Rotterdam Study, the participating general practitioners, and the pharmacists. We thank Dr Tobias A Knoch, Luc V de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and especially the national German MediGRID and Services@MediGRID part of the German D-Grid, both funded by the German Bundesministerium für Forschung und Technologie under grants #01 AK 803 A-H and #01 IG 07015 G, for access to their grid resources. AD is supported by NWO grant (vici, 918-76-619).

The SAPHIR study was partially supported by a grant from the Kamillo Eisner Stiftung to B Paulweber and by grants from the 'Genomics of Lipid-associated Disorders—GOLD' of the 'Austrian Genome Research Programme GEN-AU' to F Kronenberg.

The Young Finns Study has been financially supported by the Academy of Finland grants 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi), the Social Insurance Institution of Finland, Kuopio, Tampere, and Turku University Hospital Medical Funds (grants 9M048 and 9N035 for Teleht), the Juho Vainio Foundation, the Paavo Nurmi Foundation, the Finnish Foundation of Cardiovascular Research and Finnish Cultural Foundation, the Tampere Tuberculosis Foundation, and the Emil Aaltonen Foundation (TL). The expert technical assistance in the statistical analyses by Ville Aalto and Irina Lisinen is gratefully acknowledged.

Financial disclosures: Johanne Tremblay: Consultant Servier; Pavel Hamet: Consultant Servier; John Chalmers: Grant Servier.

AUTHOR CONTRIBUTIONS

Study design: ATi, ARSh, AHO, AGUi, AKö, BTa, BSt, BDMi, BWPe, CSFo, Che, DSSi, GEi, HKr, IHdeB, JDi, JCh, JCo, KEn, LJLa, MWo, MdAn, ORa, PMRi, PHa, RRe, RSc, SERo, TBHa, THa, TLe, UNö, UVö, VGu, PVo, GWA, WHLKa, YLi. **Study management:** ARSh, AHO, AFR, AGUi, BPa, MBo, BDMi, BWPe, CSFo, Che, DSSi, GEi, JJWa, JDi, JTr, JCh, MWo, MPi, NAu, ORa, OHFr, PMRi, PMi, PHa, RSc, SLRka, STTu, THa, TLe, UNö, VGu, PVo, YLi. **Subject recruitment:** ARSh, AHO, BPa, BDMi, CSFo, Che, CMe, CBa, DCu, DSSi, FKr, GEi, JCh, JASr, NAu, ORa, PMA, PMRi, PMi, PHa, RSc, STTu, THa, TLe, UNö, VGu, PVo, GWA. **Zebrafish experiments:** MGA, WGoe. **Interpretation of results:** ADe, ATi, APa, AVSm, AKö, AYCh, BTa, BPa, MBo, CSFo, CABö, CPa, DICh, GMMc, HKr, IHdeB, IMHe, JDi, JTr, JCh, KEn, MGA, MWo, MGo, MPi, NAu, ORa, PHa, PvdHa, RRe, RTGa, SSe, SJLba, SERo, THa, TLe, TAs, UVö, WGoe, WHLKa, YLi. **Drafting of manuscript:** ATi, AKö, CSFo, CABö, GMMc, IMHe, MGA, MGo, WGoe, WHLKa. **Statistical methods and analysis:** ADe, ATi, APa, AVSm, ATe, AKö, AYCh, BTa, BKO, BSt, BPa, CSFo, CABö, CPa, DICh, EHO, EGHO, ESA, FDGM, FKr, GMMc, GLi, HKr, IMNo, IMHe, JGu, JAn, LJROC, JDi, JCh, L-Ply, MLI, MWo, MME, MM-Nu, MGo, MOI, MOI, PAKa, SSe, S-JHw, SCo, TCo, TAs, WHLKa, YLi, ZKO. **Genotyping:** ARSh, AVSm, ATe, AFR, AGUi, BKO, BDMi, CSFo, CABö, CBa, DICh, EJAt, FRi, FKr, GLi, HGr, HSc, JGu, J-CL, LJROC, JTr, L-Ply, MHa, MdAn, PFR, PHa, PAKa, PvdHa, STTu, SLRka, TLe, UVö, YLi. **Bioinformatics:** AVSm, ATe, AFR, AJo, BTa, CABö, CPa, DICh, EHO, ESA, FRi, FKr, GMMc, GLi, HSc, HKr, IMHe, JGu, J-CL, JAn, LJROC, L-Ply, MWo, MGo, MOI, PFR, PAKa, QYa, S-JHw, SCo, VCh. **Critical review and final approval of manuscript:** All authors.

SUPPLEMENTARY MATERIAL

Table S1. Study-specific methods and full acknowledgments – stage 1 and stage 2 cohorts.

Table S2. Study-specific genotyping information for stage 1 and stage 2 studies.

Table S3. Details on kidney function measures over time in each study.

Table S4. Association results of rs12917707 at UMOD in stage 1 meta-analysis for all traits analyzed. The effect allele is T, with an allele frequency of 0.18.

Table S5. Imputation scores of SNPs analyzed in stage 1 and stage 2 meta-analysis.

Table S6. Morpholino sequences.

Figure S1. Genome-wide log₁₀ P value and QQ plots of stage 1 meta-analysis for each trait.

Supplementary material is linked to the online version of the paper at <http://www.nature.com/ki>

REFERENCES

- Coresh J, Selvin E, Stevens LA *et al.* Prevalence of chronic kidney disease in the United States. *JAMA* 2007; **298**: 2038–2047.
- Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. *Lancet* 2005; **365**: 331–340.
- KDIGO. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl* 2013; **3**: 1–150.
- Matsushita K, Selvin E, Bash LD *et al.* Change in estimated GFR associates with coronary heart disease and mortality. *J Am Soc Nephrol* 2009; **20**: 2617–2624.
- Rifkin DE, Shlipak MG, Katz R *et al.* Rapid kidney function decline and mortality risk in older adults. *Arch Intern Med* 2008; **168**: 2212–2218.
- Shlipak MG, Katz R, Kestenbaum B *et al.* Rapid decline of kidney function increases cardiovascular risk in the elderly. *J Am Soc Nephrol* 2009; **20**: 2625–2630.
- Turin TC, Coresh J, Tonelli M *et al.* One-year change in kidney function is associated with an increased mortality risk. *Am J Nephrol* 2012; **36**: 41–49.
- Turin TC, Coresh J, Tonelli M *et al.* Short-term change in kidney function and risk of end-stage renal disease. *Nephrol Dial Transplant* 2012; **27**: 3835–3843.
- Turin TC, Coresh J, Tonelli M *et al.* Change in the estimated glomerular filtration rate over time and risk of all-cause mortality. *Kidney Int* 2013; **83**: 684–691.
- Fox CS, Larson MG, Leip EP *et al.* Predictors of new-onset kidney disease in a community-based population. *JAMA* 2004; **291**: 844–850.
- Satko SG, Sedor JR, Iyengar SK *et al.* Familial clustering of chronic kidney disease. *Semin Dial* 2007; **20**: 229–236.
- O'Seaghdha CM, Fox CS. Genome-wide association studies of chronic kidney disease: what have we learned? *Nat Rev Nephrol* 2012; **8**: 89–99.
- Chambers JC, Zhang W, Lord GM *et al.* Genetic loci influencing kidney function and chronic kidney disease. *Nat Genet* 2010; **42**: 373–375.
- Köttgen A, Glazer NL, Dehghan A *et al.* Multiple loci associated with indices of renal function and chronic kidney disease. *Nat Genet* 2009; **41**: 712–717.
- Köttgen A, Pattaro C, Böger CA *et al.* New loci associated with kidney function and chronic kidney disease. *Nat Genet* 2010; **42**: 376–384.
- Pattaro C, Köttgen A, Teumer A *et al.* Genome-wide association and functional follow-up reveals new loci for kidney function. *PLoS Genet* 2012; **8**: e1002584.
- Liu CT, Garnaas MK, Tin A *et al.* Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. *PLoS Genet* 2011; **7**: e1002264.
- Okada Y, Sim X, Go MJ *et al.* Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. *Nat Genet* 2012; **44**: 904–909.
- Cheng TY, Wen SF, Astor BC *et al.* Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan. *Am J Kidney Dis* 2008; **52**: 1051–1060.
- Li L, Astor BC, Lewis J *et al.* Longitudinal progression trajectory of GFR among patients with CKD. *Am J Kidney Dis* 2012; **59**: 504–512.
- Böger CA, Gorski M, Li M *et al.* Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD. *PLoS Genet* 2011; **7**: e1002292.
- Regner KR, Harmon AC, Williams JM *et al.* Increased susceptibility to kidney injury by transfer of genomic segment from SHR onto Dahl S genetic background. *Physiol Genomics* 2012; **44**: 629–637.
- Yu L, Su Y, Pauksakon P *et al.* Integrin alpha1/Akita double-knockout mice on a Balb/c background develop advanced features of human diabetic nephropathy. *Kidney Int* 2012; **81**: 1086–1097.
- Bash LD, Coresh J, Köttgen A *et al.* Defining incident chronic kidney disease in the research setting: The ARIC Study. *Am J Epidemiol* 2009; **170**: 414–424.
- Zhang B, Gaiteri C, Bodea LG *et al.* Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell* 2013; **153**: 707–720.
- Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010; **38**: e164.
- Lash JP, Go AS, Appel LJ *et al.* Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. *Clin J Am Soc Nephrol* 2009; **4**: 1302–1311.
- Reznichenko A, Böger CA, Snieder H *et al.* UMOD as a susceptibility gene for end-stage renal disease. *BMC Med Genet* 2012; **13**: 78.
- Chen Y, Lipkowitz MS, Salem RM *et al.* Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. *Am J Nephrol* 2010; **32**: 23–30.
- Chen Y, Mahata M, Rao F *et al.* Chromogranin A regulates renal function by triggering Weibel-Palade body exocytosis. *J Am Soc Nephrol* 2009; **20**: 1623–1632.
- Chen Y, Salem RM, Rao F *et al.* Common charge-shift mutation Glu65Lys in K⁺ channel beta(1)-Subunit KCNB1: pleiotropic consequences for glomerular filtration rate and progressive renal disease. *Am J Nephrol* 2010; **32**: 414–424.
- Fung MM, Chen Y, Lipkowitz MS *et al.* Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. *Nephrol Dial Transplant* 2009; **24**: 3677–3686.
- Cooper Worobey C, Fisher ND, Cox D *et al.* Genetic polymorphisms and the risk of accelerated renal function decline in women. *PLoS One* 2009; **4**: e4787.
- Jorsal A, Tarnow L, Lajer M *et al.* The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. *Mol Genet Metab* 2008; **94**: 347–351.
- Sandholm N, Salem RM, McKnight AJ *et al.* New susceptibility loci associated with kidney disease in type 1 diabetes. *PLoS Genet* 2012; **8**: e1002921.
- Cheng W, Zhou X, Zhu L *et al.* Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with the progression of IgA nephropathy in Chinese. *Nephrol Dial Transplant* 2011; **26**: 2544–2549.
- Ferrandi M, Cusi D, Molinari I *et al.* Alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy. *J Mol Med (Berl)* 2010; **88**: 203–217.
- Trudu M, Janas S, Lanzani C *et al.* Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. *Nat Med* 2013; **19**: 1655–1660.
- Fakhro KA, Choi M, Ware SM *et al.* Rare copy number variations in congenital heart disease patients identify unique genes in left-right patterning. *Proc Natl Acad Sci USA* 2011; **108**: 2915–2920.
- Boskovski MT, Yuan S, Pedersen NB *et al.* The heterotaxy gene GALNT11 glycosylates Notch to orchestrate cilia type and laterality. *Nature* 2013; **504**: 456–459.
- Schwander M, Xiong W, Tokita J *et al.* A mouse model for nonsyndromic deafness (DFNB12) links hearing loss to defects in tip links of mechanosensory hair cells. *Proc Natl Acad Sci USA* 2009; **106**: 5252–5257.
- Bolz H, von Brederlow B, Ramirez A *et al.* Mutation of CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type 1D. *Nat Genet* 2001; **27**: 108–112.
- Bork JM, Peters LM, Riazuddin S *et al.* Usher syndrome 1D and nonsyndromic autosomal recessive deafness DFNB12 are caused by allelic mutations of the novel cadherin-like gene CDH23. *Am J Hum Genet* 2001; **68**: 26–37.
- Di Palma F, Holme RH, Bryda EC *et al.* Mutations in Cdh23, encoding a new type of cadherin, cause stereocilia disorganization in waltzer, the mouse model for Usher syndrome type 1D. *Nat Genet* 2001; **27**: 103–107.
- Siemens J, Kazmierczak P, Reynolds A *et al.* The Usher syndrome proteins cadherin 23 and harmonin form a complex by means of PDZ-domain interactions. *Proc Natl Acad Sci USA* 2002; **99**: 14946–14951.
- Uhlen M, Oksvold P, Fagerberg L *et al.* Towards a knowledge-based Human Protein Atlas. *Nat Biotechnol* 2010; **28**: 1248–1250.
- Coresh J, Astor BC, McQuillan G *et al.* Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. *Am J Kidney Dis* 2002; **39**: 920–929.
- Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. *Am J Hum Genet* 1998; **62**: 1198–1211.
- Thorisson GA, Smith AV, Krishnan L *et al.* The International HapMap Project Web site. *Genome Res* 2005; **15**: 1592–1593.
- Fuchsberger C, Taliun D, Pramstaller PP *et al.* GWATOOLBOX: an R package for fast quality control and handling of genome-wide association studies meta-analysis data. *Bioinformatics* 2012; **28**: 444–445.
- Devlin B, Roeder K. Genomic control for association studies. *Biometrics* 1999; **55**: 997–1004.
- Drummond IA, Majumdar A, Hentschel H *et al.* Early development of the zebrafish pronephros and analysis of mutations affecting pronephric function. *Development* 1998; **125**: 4655–4667.
- Kramer-Zucker AG, Wiessner S, Jensen AM *et al.* Organization of the pronephric filtration apparatus in zebrafish requires Nephric, Podocin and the FERM domain protein Mosaic eyes. *Dev Biol* 2005; **285**: 316–329.